ReviewMolecular oncology2012
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
Review in Molecular oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.Scientific reports · 2021Pooled it
- Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy.Contemporary clinical trials · 2021Trial
- Exploratory Association of 5' and 3' UTRs Variants inInternational journal of molecular sciences · 2026Article
- Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Modern developments in germline pharmacogenomics for oncology prescribing.CA: a cancer journal for clinicians · 2022Review
- Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.Cancer · 2022Article
- Toward improved models of human cancer.APL bioengineering · 2021Article
- Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.Therapeutic advances in medical oncology · 2020Article
- Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.Drugs & aging · 2019Article
- Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.Frontiers in pharmacology · 2019Review
- Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.International journal of environmental research and public health · 2018Article
- Article
- The Future Medical Science and Colorectal Surgeons.Annals of coloproctology · 2017Review
- Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Pharmaceutical research · 2017Review
- Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.Clinical genitourinary cancer · 2016Article
- Psychiatric Pharmacogenomics: How Close Are We?Biological psychiatry · 2016Article
- Application of molecular profiling in clinical trials for advanced metastatic cancers.Journal of the National Cancer Institute · 2015Article
- Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.Clinical pharmacology and therapeutics · 2014Article
- Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Clinical pharmacology and therapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomics is the study of genetic factors determining drug response or toxicity. The use of pharmacogenomics is especially desirable in oncology because the therapeutic index of oncology drugs is often narrow, the need for favorable drug response is often acute, and the consequences of drug toxicity can be life-threatening. In this review, we examine the state of pharmacogenomics in oncology, focusing only on germline pharmacogenomic variants. We consider several critical points when assessing the quality of pharmacogenomic findings and their relevance to clinical use, and discuss potential confounding factors limiting interpretation and implementation. Several of the most extensively studied drug-gene pairs (irinotecan and UGT1A1; tamoxifen and CYP2D6; 5-fluorouracil and DPYD) are inspected in depth as illustrations of both the state of advancement-and the current limitations of-present knowledge. We argue that there will likely soon be a critical mass of important germline pharmacogenomic biomarkers in oncology which deserve clinical implementation to provide optimal, personalized oncologic care. We conclude with a vision of how routine clinical testing of such germline markers could one day change the paradigm for cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.